NCT04547127View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 29, 2020

Primary Completion Date

February 4, 2021

Study Completion Date

February 4, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Convalescent anti-SARS-CoV-2 MBT Plasma

Intravenous infusion.

DRUG

Standard Medical Treatment

SMT

Trial Locations (12)

Unknown

Hospital General Universitario de Alicante, Alicante

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Universitari de Girona Doctor Josep Trueta, Girona

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat

Hospital Universitari Arnau de Vilanova, Lleida

Fundación Jimenez Diaz, Madrid

Hospital Clínico San Carlos, Madrid

Hospital Universitario La Paz, Madrid

Hospital Universitario La Princesa, Madrid

Complejo Hospitalario Universitario de Canarias, Santa Cruz de Tenerife

Hospital Clínico Universitario de Santiago -CHUS, Santiago

Hospital Universitari Joan XXIII, Tarragona

All Listed Sponsors
lead

Instituto Grifols, S.A.

INDUSTRY

NCT04547127 - A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) | Biotech Hunter | Biotech Hunter